Trials / Unknown
UnknownNCT04289207
Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, we tried to demonstrate clinical benefit of additive danazol to romiplostim therapy in patients with eltrombopag-resistant immune thrombocytopenia
Detailed description
The patients with eltrombopag-resistant immune thrombocytopenia are treated with romiplostim and danazol. The efficacy and toxicity of treatment will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romiplostim and danazol | Treatment with romiplostim and danazol |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2020-09-01
- Completion
- 2021-03-01
- First posted
- 2020-02-28
- Last updated
- 2020-02-28
Source: ClinicalTrials.gov record NCT04289207. Inclusion in this directory is not an endorsement.